Funding:

Novartis

Description

MS study evaluating the continued effectiveness, safety and tolerability of Ofatumumab in adults, between the ages 18-60, with relapsing multiple sclerosis who are transitioning from traditional anti-CD20 therapy.

Click on this link to answer a few questions to see if you qualify for this study:  https://www.lightshipclinical.com/screener/ms?utm_source=mssociety&utm_medium=advocacy